Indications |
Parenteral Postoperative nausea and vomiting Adult: Max initial dose: 2.5 mg, may be given via IM/IV admin. Additional doses of 1.25 mg may be given if necessary. Child: 2-12 yr: Max initial dose of 100 mcg//kg, may be given via IV/IM admin. Elderly: Dose reduction may be necessary. Special Populations: Elderly and debilitated patients: Reduced dosage, generally ½ adult dose. |
Contraindications |
Coma; CNS depression; phaeochromocytoma; bone marrow suppression. Patients at risk of arrhythmias, CV disorders, electrolyte imbalance, preexisting QT prolongation. |
Warnings / Precautions |
Hepatic or renal impairment; history of jaundice; CV disease; DM; hyperthyroidism; Parkinson's disease; epilepsy, depression, myasthenia gravis; prostatic hypertrophy; severe respiratory disease; blood dyscrasias. May precipitate coma, affect driving. Pregnancy; lactation; elderly. |
Adverse Reactions |
Dry mouth, constipation, micturition difficulty, blurred vision, mydriasis, delirium, agitation, catatonic-like states, insomnia, nightmares, depression, miosis, convulsions, nasal congestion. CV effects; hypersensitivity reactions, haematological disorders, extrapyramidal dysfunction. Amenorrhoea, galactorrhoea, gynaecomastia, weight gain and hyperglycaemia, and altered glucose tolerance. Pain and irritation at the Inj site. Post-op drowsiness. |
Overdose Reactions |
Symptoms may include QT prolongation and serious arrhythmias. In the presence of hypoventilation or apnea, oxygen may be used and respiration should be assisted or controlled as needed. Maintain a patent airway. The patient should be under careful observation for 24 hr; ensure adequate body warmth and fluid intake. Hypotension may occur as a result of hypovolemia, may be managed with appropriate parenteral fluid therapy. |
Drug Interactions |
Avoid concurrent use with drugs that may prolong QT interval e.g. certain antihistamines, antimalarials, calcium-channel blockers and antidepressants. May potentiate the action of other CNS depressants e.g. barbiturates, alcohol. Caution when using with drugs that may induce hypokalaemia or hypomagnesemia. See Below for More droperidol Drug Interactions |
Lab Interactions |
Minor abnormalities in liver function tests. |
Mechanism of Actions |
Droperidol acts mainly at the subcortical levels and exhibits strong sedative effects. It inhibits sympathetic postganglionic α-adrenergic receptor binding sites. It also exhibits antiemetic but has no analgesic effects. Onset: 3-10 min. Duration: 2-4 hr. |
Storage Conditions |
Parenteral: Store at 15-25°C. |
ATC Classification |
N01AX01 - droperidol ; Belongs to the class of other general anesthetics. N05AD08 - droperidol ; Belongs to the class of butyrophenone derivatives antipsychotics. |
Storage |
Parenteral: Store at 15-25°C. |
Available As |
|
Droperidol
Post Review about Droperidol Click here to cancel reply.
Droperidol Containing Brands
Droperidol is used in following diseases
Drug - Drug Interactions of Droperidol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.